Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Int Immunol ; 20(4): 525-34, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18310066

RESUMO

Carbohydrate antigens such as glycolipids and glycoproteins are over-expressed in a variety of cancers and have therefore been identified as ideal candidates for tumour vaccines. Detection of anti-carbohydrate antibodies is associated with a good prognosis in cancer patients. However, generation of an efficient adaptive immune response has been hampered by the low immunogenicity of carbohydrates due to tolerance. Here, we describe a method by which tumour-rejecting antibodies directed against carbohydrates can be elicited in two different melanoma mouse models. Thus, using the murine melanoma B16F10 over-expressing Fas ligand (FasL), we have generated mAbs against cancer carbohydrate antigens expressed by the melanoma. Importantly, passive transfer of mAbs resulted in rejection of melanoma in vivo. Their protective effect in vivo was dependent on FcR and in vitro antibody-dependent cellular phagocytosis. They were also able to delay tumour growth when injected after the tumour was established. FasL-expressing tumours as an adjuvant are a novel way to generate anti-carbohydrate antibodies able to reject tumours in vivo.


Assuntos
Anticorpos Monoclonais/biossíntese , Antígenos Glicosídicos Associados a Tumores/imunologia , Proteína Ligante Fas/imunologia , Neoplasias Pulmonares/imunologia , Melanoma Experimental/imunologia , Animais , Anticorpos Monoclonais/administração & dosagem , Especificidade de Anticorpos/imunologia , Linhagem Celular Tumoral , Humanos , Injeções Intraperitoneais , Neoplasias Pulmonares/secundário , Melanoma Experimental/secundário , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Camundongos Knockout , Receptores de IgG/deficiência , Receptores de IgG/imunologia , Ensaios Antitumorais Modelo de Xenoenxerto
2.
Cell Res ; 15(6): 430-8, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15987601

RESUMO

TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, is a member of the TNF family of proteins. Tumour cells were initially found to have increased sensitivity to TRAIL compared with normal cells, raising hopes that TRAIL would prove useful as an anti-tumor agent. The production of reliable monoclonal antibodies against TRAIL and its receptors that can stain fixed specimens will allow a thorough analysis of their expression on normal and malignant tissues. Here we report the generation of monoclonal antibodies against TRAIL and its four membrane-bound receptors (TR1-4), which have been used to stain a range of normal and malignant cells, as routinely fixed specimens. Low levels of TRAIL expression were found to be limited mostly to smooth muscle in lung and spleen as well as glial cells in the cerebellum and follicular cells in the thyroid. Expression of the TRAIL decoy receptors (TR3 and 4) was not as widespread as indicated by Northern blotting, suggesting that they may be less important for the control of TRAIL cytotoxicity than previously thought. TR1 and TR2 expression increases significantly in a number of malignant tissues, but in some common malignancies their expression was low, or patchy, which may limit the therapeutic role of TRAIL. Taken together, we have a panel of monoclonal antibodies that will allow a better assessment of the normal role of TRAIL and allow assessment of biopsy material, possibly allowing the identification of tumors that may be amenable to TRAIL therapy.


Assuntos
Glicoproteínas de Membrana/biossíntese , Neoplasias/fisiopatologia , Receptores do Fator de Necrose Tumoral/biossíntese , Fator de Necrose Tumoral alfa/biossíntese , Anticorpos Monoclonais/biossíntese , Apoptose/efeitos dos fármacos , Proteínas Reguladoras de Apoptose , Feminino , Proteínas Ligadas por GPI , Humanos , Imuno-Histoquímica/métodos , Células Jurkat , Masculino , Glicoproteínas de Membrana/imunologia , Neoplasias/patologia , Receptores do Ligante Indutor de Apoptose Relacionado a TNF , Receptores do Fator de Necrose Tumoral/imunologia , Membro 10c de Receptores do Fator de Necrose Tumoral , Coloração e Rotulagem/métodos , Ligante Indutor de Apoptose Relacionado a TNF , Distribuição Tecidual , Receptores Chamariz do Fator de Necrose Tumoral , Fator de Necrose Tumoral alfa/imunologia
3.
Cell Immunol ; 236(1-2): 78-85, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16157320

RESUMO

Tumour necrosis factor (TNF) family ligands and their corresponding receptors play important roles in the immune system and are involved in immune regulation such as lymphoid development, cell proliferation, differentiation, activation and death. Antibodies against these ligands and receptors together with Fc-fusion proteins, have been particularly useful as immunological tools in addressing the underlying involvement of these proteins in these contexts and furthermore, have given us hope in using them as potential therapeutic agents. Over last few years, there have been many additions to these ever-growing TNF family ligands and their receptors. Here, we have generated and characterised a set of monoclonal antibodies, together with mAbs from the HLDA workshop, against DcR1, DcR2, DR4, DR5, TRAIL, APRIL, BAFF, BAFF-R, BCMA, and TACI, which may be useful in phenotypic and functional studies of the role of TNF and TNF receptor family in immune function and regulation in relation to health and disease.


Assuntos
Receptores do Fator de Necrose Tumoral/imunologia , Fator de Necrose Tumoral alfa/imunologia , Animais , Anticorpos Monoclonais , Especificidade de Anticorpos , Reações Cruzadas , Feminino , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Receptores do Fator de Necrose Tumoral/genética , Receptores do Fator de Necrose Tumoral/metabolismo , Proteínas Recombinantes/imunologia , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA